Atlas Capital Advisors Inc. Sells 20,625 Shares of Organon & Co. (NYSE:OGN)

Atlas Capital Advisors Inc. trimmed its holdings in Organon & Co. (NYSE:OGN) by 85.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,546 shares of the company’s stock after selling 20,625 shares during the quarter. Atlas Capital Advisors Inc.’s holdings in Organon & Co. were worth $53,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Horizon Bancorp Inc. IN increased its stake in shares of Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares in the last quarter. Millstone Evans Group LLC bought a new position in Organon & Co. during the 4th quarter valued at approximately $29,000. Larson Financial Group LLC raised its stake in Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after buying an additional 1,734 shares during the last quarter. Riverview Trust Co boosted its holdings in Organon & Co. by 117.7% in the fourth quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after acquiring an additional 1,292 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares during the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $13.04 on Friday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a market cap of $3.36 billion, a price-to-earnings ratio of 3.91, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The business has a 50-day simple moving average of $15.16 and a two-hundred day simple moving average of $16.02. Organon & Co. has a fifty-two week low of $13.00 and a fifty-two week high of $23.10.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were issued a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 8.59%. Organon & Co.’s payout ratio is 33.63%.

Analyst Ratings Changes

Several research firms have recently issued reports on OGN. Barclays lowered their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. Finally, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.